NASDAQ:ACOR - Acorda Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $10.00
  • Forecasted Upside: 2,107.51 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.45
▼ -0.04 (-8.11%)

This chart shows the closing price for ACOR by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Acorda Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ACOR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ACOR

Analyst Price Target is $10.00
▲ +2,107.51% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Acorda Therapeutics in the last 3 months. The average price target is $10.00, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 2,107.51% upside from the last price of $0.45.

This chart shows the closing price for ACOR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 contributing investment analysts is to buy stock in Acorda Therapeutics. This rating has held steady since June 2021, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 1 sell ratings
1/13/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/13/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/12/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/10/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/8/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/8/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/7/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/7/2022

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/27/2021HC WainwrightReiterated RatingBuy$10.00Low
6/17/2021HC WainwrightUpgradeNeutral ➝ Buy$5.00 ➝ $10.00High
1/13/2021CowenBoost Price Target$5.00 ➝ $35.00High
8/11/2020Jefferies Financial GroupReiterated RatingHold$6.00Low
5/6/2020HC WainwrightReiterated RatingNeutral$36.00 ➝ $30.00High
3/9/2020HC WainwrightReiterated RatingHold$36.00High
2/16/2020JPMorgan Chase & Co.Reiterated RatingSellHigh
1/21/2020HC WainwrightReiterated RatingHold$30.00Medium
1/16/2020CowenReiterated RatingBuy$60.00Medium
12/30/2019HC WainwrightReiterated RatingHold$36.00High
12/23/2019HC WainwrightReiterated RatingHold$36.00N/A
11/5/2019HC WainwrightReiterated RatingHold$36.00High
10/24/2019JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight$8.40High
8/14/2019HC WainwrightDowngradeBuy ➝ Neutral$186.00 ➝ $36.00High
8/2/2019JPMorgan Chase & Co.Set Price TargetHold$42.00Low
8/2/2019Stifel NicolausLower Price TargetHold$72.00 ➝ $42.00High
8/2/2019WedbushLower Price TargetNeutral$48.00 ➝ $42.00High
8/2/2019Cantor FitzgeraldLower Price TargetNeutral$120.00 ➝ $72.00High
5/22/2019WedbushInitiated CoverageNeutral ➝ Neutral$72.00High
5/7/2019JPMorgan Chase & Co.Reiterated RatingHold$108.00High
3/19/2019OppenheimerReiterated RatingHoldHigh
2/15/2019Cantor FitzgeraldReiterated RatingHold$120.00High
1/23/2019HC WainwrightSet Price TargetBuy$198.00Low
1/14/2019HC WainwrightSet Price TargetBuy$198.00Low
1/7/2019CowenReiterated RatingBuy$180.00Medium
1/4/2019HC WainwrightReiterated RatingBuy$198.00High
1/2/2019OppenheimerSet Price TargetHold$108.00High
1/2/2019Cantor FitzgeraldSet Price TargetHold$192.00High
1/2/2019JPMorgan Chase & Co.Reiterated RatingHoldHigh
12/26/2018Raymond JamesReiterated RatingSellMedium
12/26/2018JPMorgan Chase & Co.Reiterated RatingNeutral ➝ HoldHigh
12/24/2018OppenheimerSet Price TargetHold ACOR$108.00High
12/24/2018Cantor FitzgeraldSet Price TargetHold ACOR$192.00High
12/11/2018The Goldman Sachs GroupDowngradeNeutral ➝ Sell$114.00 ➝ $60.00High
11/5/2018HC WainwrightReiterated RatingBuy$180.00High
11/4/2018Jefferies Financial GroupReiterated RatingHold$132.00Medium
10/31/2018JPMorgan Chase & Co.Set Price TargetHold$108.00High
10/31/2018Cantor FitzgeraldSet Price TargetHold$192.00Low
10/24/2018HC WainwrightSet Price TargetBuy$168.00High
10/12/2018JPMorgan Chase & Co.Reiterated RatingHoldLow
10/5/2018Stifel NicolausLower Price TargetHold ➝ Hold$150.00 ➝ $114.00High
9/23/2018OppenheimerSet Price TargetHold$108.00High
9/17/2018HC WainwrightSet Price TargetBuy$168.00Low
9/12/2018OppenheimerSet Price TargetHold$126.00High
9/11/2018HC WainwrightSet Price TargetBuy$186.00High
9/10/2018Cantor FitzgeraldReiterated RatingHold$192.00High
9/10/2018JPMorgan Chase & Co.Set Price TargetHold$120.00Medium
8/23/2018Cantor FitzgeraldInitiated CoverageNeutral$192.00Medium
8/7/2018Stifel NicolausBoost Price TargetHold ➝ Hold$90.00 ➝ $150.00Low
8/6/2018HC WainwrightSet Price TargetBuy$186.00High
8/2/2018OppenheimerSet Price TargetHold$126.00Medium
8/2/2018CowenReiterated RatingBuy$180.00Medium
7/30/2018Cantor FitzgeraldSet Price TargetHold$102.00Low
7/26/2018HC WainwrightSet Price TargetBuy$186.00Low
7/25/2018OppenheimerSet Price TargetHold$126.00Low
7/25/2018JPMorgan Chase & Co.Reiterated RatingHoldLow
6/11/2018HC WainwrightSet Price TargetBuy$186.00High
6/11/2018OppenheimerSet Price TargetHold$126.00High
5/30/2018HC WainwrightSet Price TargetBuy$186.00High
5/3/2018HC WainwrightSet Price TargetBuy$186.00Low
5/2/2018OppenheimerSet Price TargetHold$126.00Low
5/2/2018CowenReiterated RatingBuy$180.00High
4/2/2018HC WainwrightReiterated RatingBuy$186.00High
3/21/2018OppenheimerReiterated RatingHoldHigh
2/16/2018OppenheimerSet Price TargetHold$126.00Low
2/15/2018Piper Jaffray CompaniesUpgradeNeutral ➝ Overweight$150.60 ➝ $222.00High
2/7/2018The Goldman Sachs GroupUpgradeSell ➝ NeutralLow
1/31/2018OppenheimerBoost Price TargetMarket Perform ➝ Market Perform$108.00 ➝ $126.00Medium
1/17/2018HC WainwrightReiterated RatingBuy ➝ Buy$204.00 ➝ $186.00Medium
1/9/2018JPMorgan Chase & Co.Reiterated RatingHoldLow
12/14/2017HC WainwrightSet Price TargetBuy$204.00Medium
11/28/2017Piper Jaffray CompaniesReiterated RatingNeutral$132.00Low
11/20/2017HC WainwrightSet Price TargetBuy$204.00N/A
11/17/2017CowenReiterated RatingBuy$180.00N/A
11/16/2017Janney Montgomery ScottSet Price TargetHold$156.00 ➝ $102.00N/A
11/16/2017Raymond JamesDowngradeMarket Perform ➝ Underperform$42.00 ➝ $78.00N/A
11/16/2017Stifel NicolausDowngradeBuy ➝ Hold$156.00 ➝ $90.00N/A
11/15/2017JPMorgan Chase & Co.Lower Price TargetNeutral$114.00N/A
11/15/2017SVB LeerinkLower Price TargetMarket Perform$108.00N/A
11/15/2017OppenheimerSet Price TargetHold$108.00N/A
11/15/2017Cantor FitzgeraldLower Price TargetNeutral$108.00 ➝ $96.00N/A
11/9/2017CIBCInitiated CoverageMarket Perform ➝ Market PerformN/A
11/9/2017OppenheimerInitiated CoverageMarket Perform$162.00N/A
11/8/2017HC WainwrightInitiated CoverageBuy$210.00N/A
11/1/2017Jefferies Financial GroupBoost Price TargetHold$132.00 ➝ $150.00N/A
10/31/2017JPMorgan Chase & Co.Set Price TargetHold$144.00N/A
10/31/2017Cantor FitzgeraldReiterated RatingHold$108.00N/A
10/6/2017The Goldman Sachs GroupReiterated RatingSell ➝ Sell$120.00N/A
9/28/2017Cantor FitzgeraldReiterated RatingHold$108.00Low
8/31/2017Stifel NicolausReiterated RatingBuy$180.00 ➝ $156.00Low
8/30/2017Janney Montgomery ScottReiterated RatingHold$108.00Low
8/29/2017CowenReiterated RatingBuy$210.00Low
8/29/2017Cantor FitzgeraldReiterated RatingHold$108.00Low
7/28/2017Stifel NicolausReiterated RatingBuyLow
7/10/2017Jefferies Financial GroupInitiated CoverageHold ➝ Hold$132.00Medium
(Data available from 7/7/2017 forward)

News Sentiment Rating

0.20 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/9/2021
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/8/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/7/2022
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/9/2022
  • 0 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
4/8/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/8/2022
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/7/2022
  • 1 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
7/7/2022

Current Sentiment

  • 1 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Very Positive

Acorda Therapeutics logo
Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops ARCUS product for the treatment of acute migrain; rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa for heart failure patients. The company has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda Therapeutics, Inc. was incorporated in 1995 and is headquartered in Ardsley, New York.
Read More

Today's Range

Now: $0.45
Low: $0.44
High: $0.51

50 Day Range

MA: $0.61
Low: $0.30
High: $1.36

52 Week Range

Now: $0.45
Low: $0.28
High: $6.36

Volume

393,811 shs

Average Volume

4,117,331 shs

Market Capitalization

$6.02 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.49

Frequently Asked Questions

What sell-side analysts currently cover shares of Acorda Therapeutics?

The following equities research analysts have issued reports on Acorda Therapeutics in the last twelve months: HC Wainwright, and StockNews.com.
View the latest analyst ratings for ACOR.

What is the current price target for Acorda Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Acorda Therapeutics in the last year. Their average twelve-month price target is $10.00, suggesting a possible upside of 2,107.5%.
View the latest price targets for ACOR.

What is the current consensus analyst rating for Acorda Therapeutics?

Acorda Therapeutics currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ACOR will outperform the market and that investors should add to their positions of Acorda Therapeutics.
View the latest ratings for ACOR.

How do I contact Acorda Therapeutics' investor relations team?

Acorda Therapeutics' physical mailing address is 420 SAW MILL RIVER ROAD, ARDSLEY NY, 10502. The biopharmaceutical company's listed phone number is (914) 347-4300. The official website for Acorda Therapeutics is www.acorda.com. Learn More about contacing Acorda Therapeutics investor relations.